PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

ABSTRACT:

Background

Insulin resistance and other cardio-metabolic risk factors predict increased risk of depression and decreased response to antidepressant and mood stabilizer treatments. This proof-of-concept study tested whether administration of an insulin-sensitizing peroxisome proliferator-activated receptor (PPAR)-γ agonist could reduce bipolar depression symptom severity. A secondary objective was to determine whether levels of highly sensitive C-reactive protein and interleukin (IL)-6 predicted treatment outcome.

Methods

Patients (n = 34) with bipolar disorder (I, II, or not otherwise specified) and metabolic syndrome/insulin resistance who were currently depressed (Quick Inventory of Depressive Symptoms [QIDS] total score ≥11) despite an adequate trial of a mood stabilizer

SUBMITTER: Kemp DE 

PROVIDER: S-EPMC4113193 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature